CLINICAL OBSERVATION FROM THE TREATMENT OF ICOTINIB FOR 196 CASES WITH ADVANCED NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Gu, Qin A. [1 ]
Han, Hui B. [1 ]
Jiang, Yan L. [1 ]
Wang, Min H. [1 ]
Shi, Lei C. [1 ]
Xiong, Wen L. [1 ]
Zhao, Zhuo Y. [1 ]
Chu, Qing T. [1 ]
Pei, Jun [1 ]
机构：
[1] Jiaotong Uniyers, Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
ADVANCED NSCLC; EGFR-TKI; Icotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.11-012
引用
收藏
页码：S598 / S598
页数：1
相关论文
共 50 条
  • [31] Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib
    Mu, Yuxin
    Hao, Xuezhi
    Yang, Ke
    Ma, Di
    Wang, Shouzheng
    Xu, Ziyi
    Li, Junling
    Xing, Puyuan
    TARGETED ONCOLOGY, 2019, 14 (03) : 335 - 342
  • [32] Patterns of palliative procedures and clinical outcomes in patients with advanced non-small cell lung cancer
    Kim, Hee Jun
    Kim, Yu Jung
    Seo, Myung-Deok
    Yi, Hyeon Gyu
    Lee, Se-Hoon
    Lee, Sang-Min
    Kim, Dong-Wan
    Yang, Seok-Chul
    Lee, Choon-Taek
    Lee, Jong Seok
    Kim, Young-Whan
    Heo, Dae Seog
    LUNG CANCER, 2009, 65 (02) : 242 - 246
  • [33] The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer
    Joosten, P. J. M.
    de Langen, A. J.
    van der Noort, V.
    Monkhorst, K.
    Klomp, H. M.
    Veenhof, A. A. F. A.
    Dickhoff, C.
    Smit, E. F.
    Hartemink, K. J.
    LUNG CANCER, 2021, 161 : 141 - 151
  • [34] Nivolumab: A Review in Advanced Squamous Non-Small Cell Lung Cancer
    Gillian M. Keating
    Drugs, 2015, 75 : 1925 - 1934
  • [35] Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer
    Inoue, Akira
    PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES, 2020, 96 (07): : 266 - 272
  • [36] CHEMOTHERAPY VERSUS ERLOTINIB IN THE SECOND LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
    Fiala, Ondrej
    Pesek, Milos
    Krejci, Jana
    Sticha, Michal
    Minarik, Marek
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1259 - S1260
  • [37] Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer
    Cappuzzo, Federico
    Morabito, Alessandro
    Normanno, Nicola
    Bidoli, Paolo
    Del Conte, Alessandro
    Giannetta, Laura
    Montanino, Agnese
    Mazzoni, Francesca
    Buosi, Roberta
    Burgio, Marco Angelo
    Cerea, Giulio
    Chiari, Rita
    Cortinovis, Diego
    Finocchiaro, Giovanna
    Foltran, Luisa
    Migliorino, Maria Rita
    Tiseo, Marcello
    Ferrari, Silvia
    De Marinis, Filippo
    LUNG CANCER, 2016, 99 : 31 - 37
  • [38] Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Ardizzoni, A
    Tiseo, M
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 104 - 107
  • [39] Clinical efficacy of icotinib in patients with advanced nonsquamous non-small cell lung cancer with unknown EGFR mutation status that failed to respond to second-line chemotherapy
    Xu, Lu
    Xu, Xin-Hua
    Yuan, Cheng
    Zhang, Jia-Yu
    Tang, Xi
    Chen, Dian
    Wang, Xiao-Long
    Zeng, Guang
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (20)
  • [40] In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non-small cell lung cancer cell lines
    Wang, Min-Cong
    Liang, Xuan
    Liu, Zhi-Yan
    Cui, Jie
    Liu, Ying
    Jing, Li
    Jiang, Li-Li
    Ma, Jie-Qun
    Han, Li-Li
    Guo, Qian-Qian
    Yang, Cheng-Cheng
    Wang, Jing
    Wu, Tao
    Nan, Ke-Jun
    Yao, Yu
    ONCOLOGY REPORTS, 2015, 33 (01) : 239 - 249
12345